Tekla Life Sciences Investors

Tekla Life Sciences Investors

HQL·NYSE

$16.93

-1.5%
Financial ServicesAsset Management

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

At a Glance

Live Snapshot
Market Cap$514.81M
EPS2.9600
P/E Ratio5.72
Earnings Date06/24/2025
hql

Tekla Life Sciences Investors Street Expectations Map

HQL · NYSE

No Target Data

No analyst price targets available for hql.

hql

Tekla Life Sciences Investors Forward Estimates of Revenue

HQL · NYSE
Latest Revenue
86.39M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Forward Estimates of Net Income

HQL · NYSE
Latest Net Income
85.59M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Forward Estimates of EPS

HQL · NYSE
Latest EPS
2.96
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Forward Estimates of EBIT

HQL · NYSE
Latest EBIT
85.59M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Forward Estimates of EBITDA

HQL · NYSE
Latest EBITDA
85.59M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Forward Estimates of SG&A Expense

HQL · NYSE
Latest SG&A Expense
743.17K
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

hql

Tekla Life Sciences Investors Insider Positioning

HQL · NYSE

During the last 12 months, insiders have purchased $134K and sold $2.53M worth of HQL shares, resulting in $2.40M of net selling activity.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

7.9K

133.75K

Sold

0

0.00

Net Activity

+134K

+$134K

6-9 Months

Bought

0

0.00

Sold

131.0K

1.85M

Net Activity

-1.8M

-$1.85M

9-12 Months

Bought

0

0.00

Sold

48.9K

683.46K

Net Activity

-683K

-$683K

Top Buyers

1
PC

Pittard Christian

Director

7.9K shares1 transactions

$134K

Top Sellers

1
SCML

Saba Capital Management, L.P.

10 Percent Owner

179.9K shares11 transactions

$2.53M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $2.40M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.05:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

Balanced

1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.